Xalud Therapeutics’ Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas
Completion of enrollment for the Phase 2b study in osteoarthritis of the knee Clinical data presented at OARSI provides support for osteoarthritis program First patient dosed in the Phase 1/2a […]